Miller A B, Madalinska J B, Church T, Crawford D, Essink-Bot M L, Goel V, de Koning H J, Määttänen L, Pentikäinen T
Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
Eur J Cancer. 2001 Nov;37(17):2154-60. doi: 10.1016/s0959-8049(01)00288-x.
Decisions on policies for screening for prostate cancer require that information upon health-related quality of life (HRQL) and cost-effectiveness (CE) be available, as the lead time for some of the cases detected by screening will be very long and detriments in quality of life could have a major impact on the subjects remaining life-span. A framework within which both HRQL and cost-effectiveness of prostate cancer screening can be assessed is presented. Studies of both are ongoing in the European Randomised Study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. Preliminary information confirms that it is important to study screened subjects and controls, and not to assume that inferences derived from study of prostate cancer outside screening trials can be extrapolated to the trials. However, it will require prolonged study to enable the overall effects on quality of life, and on cost-effectiveness to be determined. Such studies are ongoing for the two trials.
关于前列腺癌筛查政策的决策需要有与健康相关的生活质量（HRQL）和成本效益（CE）方面的信息，因为通过筛查发现的一些病例的提前期会很长，生活质量的损害可能会对受试者的剩余寿命产生重大影响。本文提出了一个可用于评估前列腺癌筛查的健康相关生活质量和成本效益的框架。欧洲前列腺癌筛查随机研究和美国前列腺、肺、结肠和卵巢试验都在进行这两方面的研究。初步信息证实，研究筛查对象和对照组很重要，不能假定从筛查试验之外的前列腺癌研究中得出的推论可以外推到这些试验中。然而，需要进行长期研究才能确定对生活质量和成本效益的总体影响。这两项试验的此类研究正在进行中。
